UOC
BHVN icon

UBS O'Connor’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

UBS O'Connor’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,784,482
Closed -$572M – 1042
2022
Q3 		$572M Buy
3,784,482
+1,839,918
+95% +$273M 6.5% 1
2022
Q2 		$283M Buy
+1,944,564
New +$248M 2.95% 7

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

UBS O'Connor's BHVN Position: Q4 2022 in Review

UBS O'Connor sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 3,784,482 shares — an estimated $572M sold.

UBS O'Connor first reported a position in BHVN in Q2 2022 and held it in 2 quarters. The position peaked at $572M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • UBS O'Connor reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • UBS O'Connor sold 3,784,482 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $572M.
  • UBS O'Connor first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022 and held it in 2 quarters.
  • UBS O'Connor's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $572M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.